Clinical trials: Blood Disorder
End-stage Renal Disease
Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis
In this study, the researchers want to find out how patients who have ultrafiltration (removal of excess fluid) 6 times a week and twice-weekly dialysis (removal of excess fluid and waste products) do in terms of their blood…
- Trial name
- NCT00825318
- Testing
- Ultrafiltration
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Renal Research Institute
AIDS
Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
The objective of this study was to estimate the effects of a single dose of vardenafil on the blood pressure (BP) in subjects receiving maraviroc (MVC) (dosed to steady-state) and to assess the safety and tolerability of MVC in…
- Trial name
- NCT00853840
- Testing
- Maraviroc, Vardenafil
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Systemic Hypertension, Obesity
GAstric Bypass to Treat obEse Patients With steAdy hYpertension
Phase 3, unicentric, randomized clinical trial, with allocation concealment and intention-to-treat analysis to evaluate the efficacy of videolaparoscopic Roux-en-Y Gastroplasty to decrease the prescription of antihypertensive…
- Trial name
- GATEWAY (NCT01784848)
- Testing
- Laparoscopic Roux-en-Y gastric bypass (LRYGB), Clinical treatment
- Where
- 3 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Hospital do Coracao
Chronic Hepatitis C
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that have previously failed to respond to…
- Trial name
- STEALTHC-2 (NCT00495391)
- Testing
- Nitazoxanide, Peginterferon alfa-2a, Ribavirin
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Romark Laboratories L.C.
Depression, HIV
SSRI Effects on Depression and Immunity in HIV/AIDS
This is a 10 week, double-blind, placebo controlled trial to evaluate SSRI (Selective Serotonin Reuptake Inhibitor) effects for treatment of depression in HIV/AIDS with a focus on innate immunity and inflammation.
- Conditions
- Depression, HIV, AIDS
- Trial name
- NCT02620150
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- University of Pennsylvania
Chronic Hepatitis C, Hepatitis C (HCV)
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic hepatitis C virus (HCV) genotype (GT) 1a treatment-naïve and pegylated-interferon (pegIFN)/ribavirin (RBV) treatment-experienced adults…
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a
- Trial name
- NCT02476617
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 25 people
- Sponsor
- AbbVie
Vertebrobasilar Insufficiency, Ischemic Attack, Transient
Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
Patients with blockage of the blood vessels that supply blood to the back of the brain, known as vertebrobasilar disease (VBD), are at risk of having a stroke or temporary symptoms of a stroke known as transient ischemic attack…
- Conditions
- Vertebrobasilar Insufficiency, Ischemic Attack, Transient, Cerebrovascular Disorder, Brain Ischemia
- Trial name
- VERiTAS (NCT00590980)
- Where
- 6 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- University of Illinois Chicago
Fanconi Anemia
Eltrombopag for Fanconi Anemia
Background: Fanconi anemia is a genetic disease. Some people with it have reduced blood cell counts. This means their bone marrow no longer works properly.
- Trial name
- NCT03206086
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HIV/AIDS, Medication Adherence
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
Introduction of antiretroviral therapy (ART) has transformed HIV-infection from a fatal to manageable disease but adherence to ART remains critical to optimize outcomes.
- Trial name
- NCT02797262
- Testing
- Proteus digital health feedback (PDHF) system
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of California, Los Angeles
Leukemia
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in…
- Trial name
- NCT00723203
- Testing
- panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
This randomized phase II trial studies how well ixazomib and dexamethasone or ixazomib, dexamethasone, and lenalidomide work based on the presence of the rearrangement of a gene called nuclear factor of kappa light polypeptide…
- Trial name
- NCT02765854
- Testing
- Dexamethasone, Ixazomib, Lenalidomide
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Visceral Leishmaniosis, HIV-infection/Aids
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral leishmaniosis (VL) is widely reported in Ethiopia, with about 30% of cases being associated with human immunodeficiency virus (HIV).
- Trial name
- NCT01360762
- Testing
- Pentamidine
- Where
- 3 sites in Ethiopia
- Volunteers
- 74 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Multiple Myeloma
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding…
- Trial name
- NCT01548573
- Testing
- Dexamethasone, Tandem autologous stem cell transplant, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Iowa
Multiple Myeloma
A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.
- Trial name
- NCT00747123
- Testing
- ACE-011
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- Celgene
Myelodysplastic Syndrome, MDS
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
Revlimid® (Lenalidomide) is indicated for a type of blood cancer, myelodysplastic syndrome (MDS), at 10mg for a specific type of myelodysplastic syndrome with a genetic abnormality called "deletion 5q" in Low and Intermediate-1…
- Conditions
- Myelodysplastic Syndrome, MDS, Low to Intermediate-1 MDS, Non-deletion 5q
- Trial name
- NCT00699842
- Testing
- Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hepatitis B, Vertical Transmission of Infectious Disease
Arresting Vertical Transmission of Hepatitis B Virus
The purpose of this pilot study is to demonstrate the feasibility of adding HBV screening and treatment of pregnant women to the existing HIV PMTCT platform in order to prevent mother-to-child transmission of hepatitis B virus.
- Trial name
- AVERT-HBV (NCT03567382)
- Testing
- Tenofovir Disoproxil Fumarate, Monovalent HBV vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 179 people
- Sponsor
- University of North Carolina, Chapel Hill
Hypereosinophilic Syndrome
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Mepolizumab is a humanized monoclonal antibody. In conditions where eosinophilia is considered to play an important part in the pathology, including eosinophilic asthma, HES, and eosinophilic granulomatosis with polyangiitis, a…
- Trial name
- NCT02836496
- Testing
- Mepolizumab 300 mg, Active OCS capsules (5 mg prednisolone or prednisone)
- Where
- 43 sites in United States, Argentina and 11 more
- Volunteers
- 108 people
- Sponsor
- GlaxoSmithKline
Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other
Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.
- Trial name
- NCT03219723
- Testing
- Vonoprazan, Amoxicillin hydrate, Clarithromycin
- Where
- Japan
- Volunteers
- 560 people
- Sponsor
- Takeda
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
This study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and…
- Trial name
- FUSION NHL 001 (NCT02733042)
- Testing
- Durvalumab, Lenalidomide, Rituximab
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 106 people
- Sponsor
- Celgene
Hemostasis, Oral Contraceptive
A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
This study is being conducted to evaluate the impact of a 91-day extended cycle oral contraceptive compared to two 28-day oral contraceptive regimens on hemostatic parameters in healthy women.
- Trial name
- NCT01252186
- Testing
- 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
- Where
- 24 sites in United States, Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Teva Women's Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.